Sun Pharma to acquire Japan's Pola Pharma for $1 mn; to strengthen presence in dermatology segment

Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables.

Press Trust of India November 27, 2018 11:20:32 IST
Sun Pharma to acquire Japan's Pola Pharma for $1 mn; to strengthen presence in dermatology segment

New Delhi: Sun Pharma on Monday said it will acquire Japan-based Pola Pharma for around $1 million to strengthen its presence in dermatology segment across the globe.

The company has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharmaceutical Industries said in a statement.

Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables.

Sun Pharma to acquire Japans Pola Pharma for 1 mn to strengthen presence in dermatology segment

Representational image. Reuters

It also has R&D capabilities to develop new technologies and formulations.

"This acquisition is in line with our strategy to strengthen our global dermatology presence. Pola Pharma is a leading dermatology company and it will help us launch our speciality and generic dermatology products in the Japanese market in future," Sun Pharma Executive Vice-President Kirti Ganorkar said.

Sun Pharma Japan Country Head Junichi Nakamichi said that by combining its global strengths with Pola Pharma's local expertise, the company will have a great opportunity to further strengthen its presence in Japan, especially in dermatology.

Pola Pharma had an annual revenue of around $108 million and net loss of $7 million for the 12 months ended December 2017 on a consolidated basis.

"The equity consideration, on the debt-free and cash-free basis, for the 100 per cent stake in Pola Pharma is around $1 million," Sun Pharma said.

The transaction is expected to close on or before January 31, 2019, subject to completion of closing conditions, it added.

Sun Pharma forayed into the Japanese prescription market in 2016, with the acquisition of 14 established prescription brands from Novartis. The size of the Japanese pharmaceutical market is estimated at $84.8 billion, accounting for around 7.5 per cent of the $1.13-trillion global pharmaceutical market.

Sun Pharma shares Monday ended 2.88 per cent down at Rs 510.65 on the BSE.

Updated Date:

Subscribe to Moneycontrol Pro at ₹499 for the first year. Use code PRO499. Limited period offer. *T&C apply

also read

Harvard professor sparks outrage among international scholars after he claims Japan's 'comfort women' were contractual sex workers
World

Harvard professor sparks outrage among international scholars after he claims Japan's 'comfort women' were contractual sex workers

In a recent academic paper, Harvard University professor J Mark Ramseyer rejected a wide body of research finding that Japan’s so-called “comfort women” were forced to work at military brothels during World War II. Ramseyer instead argued that the women willingly entered into contracts as sex workers.

Netflix to release docu-drama series Age of Samurai: Battle for Japan on 24 February
Entertainment

Netflix to release docu-drama series Age of Samurai: Battle for Japan on 24 February

Netflix show Age of Samurai revolves around warring kingdoms of feudal Japan.

Fukushima plant operator claims seismometers 'out of order' for a year before 15 Feb quake
World

Fukushima plant operator claims seismometers 'out of order' for a year before 15 Feb quake

Officials acknowledged that multiple seismometers had failed several months ago, and hadn't been repaired since.